Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer
Soleno Therapeutics, Inc. (SLNO)
Last soleno therapeutics, inc. earnings: 5/13 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.soleno.life/investor-overview
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transition. Mrs. Fulk brings to Soleno more than two decades of public company experience in leading financial strategy, investor relations, financial reporting, and operational efficiency, with a diverse career progression that includes 15 years at Eli Lilly. “Jennifer has a proven track record of financial leadership, building high-performing organizations, scaling businesses internationally, and driving profitable growth, and I am very pleased to welcome her to the Soleno team,” stated Dr. Anish
Show less
Read more
Impact Snapshot
Event Time:
SLNO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLNO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLNO alerts
High impacting Soleno Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SLNO
News
- Soleno Therapeutics (SLNO) had its price target lowered by HC Wainwright from $120.00 to $100.00. They now have a "buy" rating on the stock.MarketBeat
- Soleno Therapeutics, Inc. (SLNO) Revenue Tops Expectations With $91.7M in Q4 Results, TD Cowen Maintains Buy [Yahoo! Finance]Yahoo! Finance
- Wells Fargo Cuts PT on Soleno Therapeutics (SLNO) to $110 From $114 – Here's Why [Yahoo! Finance]Yahoo! Finance
- Soleno Profitability Milestone And CFO Shift Raise Valuation Questions [Yahoo! Finance]Yahoo! Finance
- Soleno Therapeutics, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
SLNO
Earnings
- 2/25/26 - Beat
SLNO
Sec Filings
- 3/4/26 - Form 4
- 3/4/26 - Form 3
- 2/26/26 - Form 8-K
- SLNO's page on the SEC website